الفهرس 
-Virology, genotypes and structure of HCVOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
HCV is estimated to infect 170 million people who represent about 3% of the world‘s population. The World Health Organization has referred to HCV as a ―viral time bomb‖ as chronically infected individuals are at risk for developing cirrhosis, HCC and non-Hodgkin‘s lymphoma. In Egypt, the epidemiological and social situation differs from that of Western countries. Because HCV prevalence is high worldwide and other viral co-infection such as HBV, CMV and EBV infection is recoded among HCV patients, which could badly be affecting the liver status and lead to hepatitis. Co-infection of different viruses and HCV could accelerate the disease pathogenesis and dramatically diminish its treatment.
In the present study, one hundred and eighty-four patients chronically infected with HCV from Kafer El Shiekh Liver and Heart Institute, Egypt during the period between March 2015 and April 2016 were enrolled in the present study. The patients included eighty-four females and one hundred males, with age range (27-56) with a mean of (42.04±6.99) years. To evaluate the clinical, haematological and biochemical alteration, the study population was divided into six groups: Group-I: Eighty-four patients with chronic HCV infection without other viral infection.
Group-II: Three patients with concomitant HBV and chronic HCV infections.
Group-III: Ten patients with concomitant EBV and chronic HCV infections.
Group-IV: Sixty-five patients with concomitant CMV and chronic HCV infections serologically detected.